Akebia Therapeutics Inc AKBA.OQ AKBA.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The Cambridge Massachusetts-based company is expected to report a 37.6% increase in revenue to $44.883 million from $32.61 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Akebia Therapeutics Inc is for a loss of 4 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Akebia Therapeutics Inc is $6.75, above its last closing price of $2.34.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.09 | -0.08 | -0.10 | Missed | -25 |
Sep. 30 2024 | -0.07 | -0.06 | -0.10 | Missed | -57.9 |
Jun. 30 2024 | -0.05 | -0.05 | -0.04 | Beat | 25 |
Mar. 31 2024 | -0.08 | -0.08 | -0.09 | Missed | -17.4 |
Dec. 31 2023 | -0.04 | -0.04 | 0.00 | Beat | 100 |
Sep. 30 2023 | -0.07 | -0.08 | -0.08 | Met | 5.9 |
Jun. 30 2023 | -0.02 | -0.02 | -0.06 | Missed | -140 |
Mar. 31 2023 | -0.15 | -0.15 | -0.14 | Beat | 6.7 |
This summary was machine generated May 6 at 12:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。